CD8A and neoplasm: Since FOLFOX therapy maintains tumor specific CD8 T cells in a non-dysfunctional/terminally exhausted state, this may provide an additive or synergistic effect to current immune checkpoint blockade in human patients, which we demonstrate in our tumor model.